Results 121 to 130 of about 847 (163)
Some of the next articles are maybe not open access.
Pain Management, 2023
Aim: To investigate potential pharmacokinetic interactions between atogepant and esomeprazole. Methods: Atogepant, esomeprazole, or both were administered to 32 healthy adults in an open-label, nonrandomized, crossover study. Systemic exposure (area under the plasma concentration-time curve [AUC] and peak plasma concentration [Cmax]) for atogepant ...
Jonathan Rojo +2 more
exaly +3 more sources
Aim: To investigate potential pharmacokinetic interactions between atogepant and esomeprazole. Methods: Atogepant, esomeprazole, or both were administered to 32 healthy adults in an open-label, nonrandomized, crossover study. Systemic exposure (area under the plasma concentration-time curve [AUC] and peak plasma concentration [Cmax]) for atogepant ...
Jonathan Rojo +2 more
exaly +3 more sources
Atogepant for the Prevention of Episodic Migraine in Adults: A Systematic Review and Meta-Analysis of Efficacy and Safety [PDF]
Neurology and Therapy, 2022 INTRODUCTION The inhibition of the calcitonin gene-related peptide (CGRP) pathway has attracted interest in pharmacological research on migraine.
Simona Lattanzi +2 more
exaly +6 more sources
Headache, 2023 Objective: To assess long-term safety, tolerability, and efficacy of once-daily oral atogepant 60 mg in adults with migraine. Background: Atogepant is an oral, small-molecule, calcitonin gene–related peptide receptor antagonist approved for the ...
Susan Hutchinson +2 more
exaly +2 more sources
Lancet, The, 2023 Background: In this study, we aimed to evaluate the efficacy, safety, and tolerability of atogepant for the preventive treatment of chronic migraine.
Rosa Miceli +2 more
exaly +2 more sources
Drugs of Today, 2022
Atogepant is a selective oral, small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist that has been approved for preventive treatment of migraine. CGRP is a neuropeptide involved in vasodilation and cerebrovascular regulation. CGRP is the most potent vasoactive constituent of the cerebrovascular trigeminal neuronal system and has a ...
Kate, Bedrin, Jessica, Ailani
openaire +2 more sources
Atogepant is a selective oral, small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist that has been approved for preventive treatment of migraine. CGRP is a neuropeptide involved in vasodilation and cerebrovascular regulation. CGRP is the most potent vasoactive constituent of the cerebrovascular trigeminal neuronal system and has a ...
Kate, Bedrin, Jessica, Ailani
openaire +2 more sources
Canadian Journal of Health Technologies, 2023
CADTH recommends that Qulipta be reimbursed by public drug plans for the prevention of episodic migraine, if certain conditions are met. Qulipta should only be reimbursed for adults with episodic migraine, according to the criteria used by public drug plans for other calcitonin gene-related peptide (CGRP) inhibitors for the prevention of ...
openaire +1 more source
CADTH recommends that Qulipta be reimbursed by public drug plans for the prevention of episodic migraine, if certain conditions are met. Qulipta should only be reimbursed for adults with episodic migraine, according to the criteria used by public drug plans for other calcitonin gene-related peptide (CGRP) inhibitors for the prevention of ...
openaire +1 more source
CephalalgiaAimLong-term data for oral calcitonin gene-related peptide receptor antagonist, atogepant, in episodic migraine (EM) has been reported. This is the first report on one-year outcomes in participants with chronic migraine (CM) and in the EM population with
Soo-Jin Cho +2 more
exaly +2 more sources
Atogepant for Migraine Prevention: A Systematic Review of Efficacy and Safety
Clinical Drug Investigation, 2022Atogepant is the latest calcitonin gene-related peptide (CGRP) antagonist approved exclusively for prophylaxis of episodic migraine and is administered orally in doses of 10-60 mg/day. This article aims to provide a systematic review of the efficacy and safety of atogepant in migraine prevention.The literature was searched in different databases, i.e.,
Alok Singh, Mahesh Kumar Balasundaram
openaire +2 more sources
Expert Review of NeurotherapeuticsIntroduction: Rimegepant and atogepant, two innovative oral medications for the treatment of migraine, are gaining prominence in the treatment of migraine.
Paolo Martelletti +2 more
exaly +2 more sources